{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:56:02Z","timestamp":1777895762462,"version":"3.51.4"},"reference-count":17,"publisher":"Georg Thieme Verlag KG","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1055\/a-2295-1592","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T11:45:13Z","timestamp":1728560713000},"page":"1263-1269","source":"Crossref","is-referenced-by-count":1,"title":["Lysosomale Speicherkrankheiten \u2013  Morbus Fabry und Morbus Gaucher"],"prefix":"10.1055","volume":"149","author":[{"given":"Lucia","family":"Segura Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia B.","family":"Hennermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0396-8362","authenticated-orcid":false,"given":"Andr\u00e9","family":"Lollert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"FM Platt","year":"2018","journal-title":"Nature Reviews Disease Primers 2018"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/CGE.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"L Echevarria","year":"2016","journal-title":"Clin Genet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"5548445","DOI":"10.1155\/2021\/5548445","article-title":"Anderson-Fabry Disease: From Endothelial Dysfunction to Emerging Therapies","volume":"2021","author":"CA Stamerra","year":"2021","journal-title":"Adv Pharmacol Pharm Sci"},{"issue":"04","key":"ref5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"A Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/S10157-021-02058-Z","article-title":"Pathology and pathogenic pathways in fabry nephropathy","volume":"25","author":"S Feriozzi","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"ref7","volume-title":"Deutsche Gesellschaft f\u00fcr Kardiologie \u2013 Herz-und Kreislaufforschung e.V. (Hrsg.) ESC Pocket Guidelines. Kardiomyopathien (Version 2023)","author":"B Meder","year":"2023"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1161\/CIRCIMAGING.113.000482","article-title":"T\u2081 mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex","volume":"6","author":"RB Thompson","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/J.1529-8027.2011.00365.X","article-title":"Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy","volume":"16","author":"N \u00dc\u00e7eyler","year":"2011","journal-title":"Journal of the Peripheral Nervous System"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: A Review in Fabry Disease","volume":"79","author":"EH Mccafferty","year":"2019","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/S13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"M Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ejim.2006.07.005","article-title":"Epidemiology and natural history of Gaucher\u2019s disease","volume":"17","author":"A Mehta","year":"2006","journal-title":"Eur J Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/PHMT.S12499","article-title":"Prevalence and management of Gaucher disease","volume":"2","author":"A Burrow","year":"2011","journal-title":"Pediatric Health, Medicine and Therapeutics"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.2214\/AJR.06.1410","article-title":"Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher\u2019s disease using the bone marrow burden score","volume":"188","author":"PL Robertson","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/AJH.26675","article-title":"Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry","volume":"97","author":"BE Rosenbloom","year":"2022","journal-title":"Am J Hematol"},{"issue":"04","key":"ref16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/CELLS8040364","article-title":"GBA, Gaucher Disease, and Parkinson\u2019s Disease: From Genetic to Clinic to New Therapeutic Approaches","volume":"8","author":"GM Riboldi","year":"2019","journal-title":"Cells"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/S40265-015-0468-9\/METRICS","article-title":"Eliglustat: A Review in Gaucher Disease Type 1","volume":"75","author":"LJ Scott","year":"2015","journal-title":"Drugs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/J.YMGME.2022.11.002","article-title":"Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study","volume":"138","author":"PB Deegan","year":"2023","journal-title":"Mol Genet Metab"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2295-1592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T15:02:39Z","timestamp":1730818959000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2295-1592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":17,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,10,9]]},"published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2295-1592","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}